documents
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
67 rows where agency_id = "FDA" and document_type = "Notice" sorted by comment_end_date descending
This data as json, CSV (advanced)
Suggested facets: subtype, posted_date, posted_year, posted_month, comment_start_date, comment_end_date, posted_date (date), comment_start_date (date), comment_end_date (date), last_modified (date)
agency_id 1
- FDA · 67 ✖
| id | agency_id | docket_id | title | document_type | subtype | posted_date | posted_year | posted_month | comment_start_date | comment_end_date ▲ | last_modified | fr_doc_num | open_for_comment | withdrawn | object_id |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FDA-2026-N-0131-0001 | FDA | FDA-2026-N-0131 | FDA Rare Disease Innovation Hub Future Programming; Request for Comments | Notice | Request for Comments | 2026-01-30 | 2026 | 1 | 2026-01-30 | 2027-01-01 | 2026-05-05 09:00:20 | 2026-01903 | 1 | 0 | 09000064b91893ee |
| FDA-2016-D-1280-0005 | FDA | FDA-2016-D-1280 | Electronic Submission of Postmarketing Individual Case Safety Reports to the Food and Drug Administration Adverse Event Monitoring System Using International Council of Harmonisation E2B(R3) Data Standards; Regional Data Elements and Implementation Schedule | Notice | Announcement | 2026-04-06 | 2026 | 4 | 2026-04-06 | 2026-10-02 | 2026-04-07 09:00:25 | 2026-06660 | 1 | 0 | 09000064b9253dbc |
| FDA-2025-E-2426-0006 | FDA | FDA-2025-E-2426 | Determination of Regulatory Review Period for Purposes of Patent Extension; BLUJEPA | Notice | Determinations | 2026-02-13 | 2026 | 2 | 2026-02-13 | 2026-08-13 | 2026-02-13 20:03:13 | 2026-02901 | 1 | 0 | 09000064b91aa6fb |
| FDA-2025-E-0152-0006 | FDA | FDA-2025-E-0152 | Determination of Regulatory Review Period for Purposes of Patent Extension; COBENFY | Notice | Determinations | 2026-02-06 | 2026 | 2 | 2026-02-06 | 2026-08-06 | 2026-02-06 20:05:43 | 2026-02388 | 1 | 0 | 09000064b919467e |
| FDA-2025-E-0153-0006 | FDA | FDA-2025-E-0153 | Determination of Regulatory Review Period for Purposes of Patent Extension; COBENFY | Notice | Determinations | 2026-02-06 | 2026 | 2 | 2026-02-06 | 2026-08-06 | 2026-02-06 20:06:34 | 2026-02388 | 1 | 0 | 09000064b919467f |
| FDA-2024-E-3539-0006 | FDA | FDA-2024-E-3539 | Determination of Regulatory Review Period for Purposes of Patent Extension; BEQVEZ | Notice | Determinations | 2026-02-06 | 2026 | 2 | 2026-02-06 | 2026-08-06 | 2026-02-14 13:19:52 | 2026-02387 | 1 | 0 | 09000064b9195b4d |
| FDA-2025-E-0154-0006 | FDA | FDA-2025-E-0154 | Determination of Regulatory Review Period for Purposes of Patent Extension; COBENFY | Notice | Determinations | 2026-02-06 | 2026 | 2 | 2026-02-06 | 2026-08-06 | 2026-02-06 20:07:01 | 2026-02388 | 1 | 0 | 09000064b9195c17 |
| FDA-2026-N-3273-0001 | FDA | FDA-2026-N-3273 | Financial Transparency and Efficiency of the Prescription Drug User Fee Act, Biosimilar User Fee Act, and Generic Drug User Fee Amendments; Public Meeting; Request for Comments | Notice | Request for Comments | 2026-04-15 | 2026 | 4 | 2026-04-15 | 2026-07-24 | 2026-04-15 17:05:22 | 2026-07248 | 1 | 0 | 09000064b9282224 |
| FDA-2025-N-6895-0001 | FDA | FDA-2025-N-6895 | Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments—Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List | Notice | Request for Comments | 2026-04-16 | 2026 | 4 | 2026-04-16 | 2026-07-23 | 2026-05-17 09:00:23 | 2026-07361 | 1 | 0 | 09000064b92865ab |
| FDA-2026-N-4126-0001 | FDA | FDA-2026-N-4126 | Azodicarbonamide (ADA); Request for Information | Notice | Requests for Information (RFI) | 2026-05-13 | 2026 | 5 | 2026-05-13 | 2026-07-14 | 2026-05-13 17:13:38 | 2026-09508 | 1 | 0 | 09000064b92d17fd |
| FDA-2026-N-3098-0001 | FDA | FDA-2026-N-3098 | Agency Information Collection Activities; Proposed Collection; Comment Request; Postmarketing Adverse Experience Reporting | Notice | 60 Day Proposed Information Collection | 2026-05-13 | 2026 | 5 | 2026-05-13 | 2026-07-14 | 2026-05-13 16:56:28 | 2026-09543 | 1 | 0 | 09000064b92d4966 |
| FDA-2026-N-2526-0001 | FDA | FDA-2026-N-2526 | Butylated Hydroxytoluene (BHT); Request for Information | Notice | Requests for Information (RFI) | 2026-05-13 | 2026 | 5 | 2026-05-13 | 2026-07-14 | 2026-05-13 17:01:00 | 2026-09507 | 1 | 0 | 09000064b92d4931 |
| FDA-2026-N-0005-0001 | FDA | FDA-2026-N-0005 | Biomarker Incubator: Urinary Kidney Safety Biomarkers; Request for Information | Notice | Requests for Information (RFI) | 2026-05-13 | 2026 | 5 | 2026-05-13 | 2026-07-14 | 2026-05-13 17:06:21 | 2026-09533 | 1 | 0 | 09000064b92d48f3 |
| FDA-2023-N-0119-0020 | FDA | FDA-2023-N-0119 | Fiscal Year 2026 Generic Drug Science and Research Initiatives Workshop; Public Workshop; Request for Comments | Notice | Request for Comments | 2026-02-27 | 2026 | 2 | 2026-02-27 | 2026-07-11 | 2026-04-14 09:00:18 | 2026-03961 | 1 | 0 | 09000064b91e326c |
| FDA-2026-N-3070-0001 | FDA | FDA-2026-N-3070 | Agency Information Collection Activities; Proposed Collection; Comment Request; National Youth Tobacco Survey | Notice | 60 Day Proposed Information Collection | 2026-05-04 | 2026 | 5 | 2026-05-04 | 2026-07-07 | 2026-05-04 19:19:25 | 2026-08604 | 1 | 0 | 09000064b92c115c |
| FDA-2018-N-3240-0377 | FDA | FDA-2018-N-3240 | List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act | Notice | Request for Comments | 2026-05-01 | 2026 | 5 | 2026-05-01 | 2026-07-01 | 2026-05-17 09:00:24 | 2026-08552 | 1 | 0 | 09000064b92bb724 |
| FDA-2026-N-3499-0001 | FDA | FDA-2026-N-3499 | Obesity and Drug Dosing: Clinical Pharmacology Considerations; Request for Comments | Notice | Request for Comments | 2026-05-01 | 2026 | 5 | 2026-05-01 | 2026-07-01 | 2026-05-02 09:00:17 | 2026-08521 | 1 | 0 | 09000064b92bb7fb |
| FDA-2026-N-3947-0001 | FDA | FDA-2026-N-3947 | Impacts of Patient-Focused Drug Development Meetings; Establishment of a Public Docket; Request for Information and Comments | Notice | Request for Comments | 2026-05-01 | 2026 | 5 | 2026-05-01 | 2026-07-01 | 2026-05-09 09:00:22 | 2026-08524 | 1 | 0 | 09000064b92bb6d7 |
| FDA-2026-N-4268-0001 | FDA | FDA-2026-N-4268 | Medical Devices; Exemptions From Premarket Notification: Certain Class II Devices; Request for Comments | Notice | Request for Comments | 2026-05-01 | 2026 | 5 | 2026-05-01 | 2026-07-01 | 2026-05-09 09:00:22 | 2026-08499 | 1 | 0 | 09000064b92bb7b3 |
| FDA-2026-N-3532-0001 | FDA | FDA-2026-N-3532 | Agency Information Collection Activities; Proposed Collection; Comment Request; Good Laboratory Practice Requirements for Nonclinical Laboratory Studies | Notice | 60 Day Proposed Information Collection | 2026-04-30 | 2026 | 4 | 2026-04-30 | 2026-06-30 | 2026-05-02 09:00:17 | 2026-08371 | 1 | 0 | 09000064b92b7fb3 |
| FDA-2026-N-2366-0001 | FDA | FDA-2026-N-2366 | Commissioner’s National Priority Voucher (CNPV) Pilot Program; Public Hearing; Request for Comments | Notice | Request for Comments | 2026-03-23 | 2026 | 3 | 2026-03-23 | 2026-06-30 | 2026-05-01 09:00:14 | 2026-05573 | 1 | 0 | 09000064b922c21a |
| FDA-2026-N-1321-0001 | FDA | FDA-2026-N-1321 | ChemoCentryx, Inc.; Proposal To Withdraw Approval of New Drug Application for TAVNEOS (Avacopan) Capsule, 10 Milligrams; Opportunity for a Hearing | Notice | Withdrawal | 2026-04-30 | 2026 | 4 | 2026-04-30 | 2026-06-30 | 2026-05-16 09:00:16 | 2026-08455 | 1 | 0 | 09000064b92b7e81 |
| FDA-2026-N-2917-0001 | FDA | FDA-2026-N-2917 | Agency Information Collection Activities; Proposed Collection; Comment Request; Generic Clearance for Qualitative Data To Support Social and Behavioral Research for Food, Dietary Supplements, Cosmetics, and Animal Food and Feed | Notice | 60 Day Proposed Information Collection | 2026-04-17 | 2026 | 4 | 2026-04-17 | 2026-06-17 | 2026-04-17 16:47:09 | 2026-07501 | 1 | 0 | 09000064b9289353 |
| FDA-2026-N-3099-0001 | FDA | FDA-2026-N-3099 | Agency Information Collection Activities; Proposed Collection; Comment Request; Radioactive Drug Research Committees | Notice | 60 Day Proposed Information Collection | 2026-04-17 | 2026 | 4 | 2026-04-17 | 2026-06-17 | 2026-04-17 16:55:18 | 2026-07507 | 1 | 0 | 09000064b9289303 |
| FDA-2025-E-0501-0006 | FDA | FDA-2025-E-0501 | Determination of Regulatory Review Period for Purposes of Patent Extension; UNLOXCYT | Notice | Determinations | 2026-04-16 | 2026 | 4 | 2026-04-16 | 2026-06-16 | 2026-04-16 17:49:56 | 2026-07422 | 1 | 0 | 09000064b928671f |
| FDA-2025-E-0502-0006 | FDA | FDA-2025-E-0502 | Determination of Regulatory Review Period for Purposes of Patent Extension; UNLOXCYT | Notice | Determinations | 2026-04-16 | 2026 | 4 | 2026-04-16 | 2026-06-16 | 2026-04-16 17:53:26 | 2026-07422 | 1 | 0 | 09000064b9286364 |
| FDA-2026-N-3400-0001 | FDA | FDA-2026-N-3400 | Agency Information Collection Activities; Proposed Collection; Comment Request; Orphan Drugs | Notice | 60 Day Proposed Information Collection | 2026-04-16 | 2026 | 4 | 2026-04-16 | 2026-06-16 | 2026-04-18 09:00:22 | 2026-07423 | 1 | 0 | 09000064b9286561 |
| FDA-2026-N-3240-0001 | FDA | FDA-2026-N-3240 | Agency Information Collection Activities; Proposed Collection; Comment Request; Importation of Prescription Drugs | Notice | 60 Day Proposed Information Collection | 2026-04-16 | 2026 | 4 | 2026-04-16 | 2026-06-16 | 2026-04-16 18:04:30 | 2026-07421 | 1 | 0 | 09000064b92866e7 |
| FDA-2025-N-1600-0003 | FDA | FDA-2025-N-1600 | Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; The Real Cost Campaign Outcomes Evaluation Study: Cohort 3 | Notice | 30 Day Proposed Information Collection | 2026-05-13 | 2026 | 5 | 2026-05-13 | 2026-06-13 | 2026-05-13 17:17:21 | 2026-09448 | 1 | 0 | 09000064b92d4828 |
| FDA-2026-N-4492-0001 | FDA | FDA-2026-N-4492 | Drug Repurposing for Unmet Medical Needs; Request for Information | Notice | Requests for Information (RFI) | 2026-05-12 | 2026 | 5 | 2026-05-12 | 2026-06-12 | 2026-05-17 09:00:25 | 2026-09366 | 1 | 0 | 09000064b92d15f4 |
| FDA-2026-N-2742-0001 | FDA | FDA-2026-N-2742 | Agency Information Collection Activities; Proposed Collection; Comment Request; Color Additive Certification | Notice | 60 Day Proposed Information Collection | 2026-04-10 | 2026 | 4 | 2026-04-10 | 2026-06-10 | 2026-04-10 18:01:37 | 2026-06936 | 1 | 0 | 09000064b926825a |
| FDA-2026-N-2743-0001 | FDA | FDA-2026-N-2743 | Agency Information Collection Activities; Proposed Collection; Comment Request; Submission of Petitions: Food Additive, Color Additive (Including Labeling), Submission of Information to a Master File in Support of Petitions; and Electronic Submission Using Food and Drug Administration Form 3503 | Notice | 60 Day Proposed Information Collection | 2026-04-10 | 2026 | 4 | 2026-04-10 | 2026-06-10 | 2026-04-20 09:00:32 | 2026-06935 | 1 | 0 | 09000064b926821b |
| FDA-2026-N-2915-0001 | FDA | FDA-2026-N-2915 | Agency Information Collection Activities; Proposed Collection; Comment Request; Premarket Approval of Medical Devices | Notice | 60 Day Proposed Information Collection | 2026-04-10 | 2026 | 4 | 2026-04-10 | 2026-06-10 | 2026-04-10 17:47:50 | 2026-06906 | 1 | 0 | 09000064b9268328 |
| FDA-2026-N-2431-0001 | FDA | FDA-2026-N-2431 | Agency Information Collection Activities; Proposed Collection; Comment Request; Administrative Practices and Procedures; Formal Hearings | Notice | 60 Day Proposed Information Collection | 2026-04-07 | 2026 | 4 | 2026-04-07 | 2026-06-09 | 2026-05-12 09:00:14 | 2026-06719 | 1 | 0 | 09000064b9255485 |
| FDA-2025-E-0863-0006 | FDA | FDA-2025-E-0863 | Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY | Notice | Determinations | 2026-04-03 | 2026 | 4 | 2026-04-03 | 2026-06-03 | 2026-04-03 17:37:03 | 2026-06478 | 1 | 0 | 09000064b924cccb |
| FDA-2025-E-0845-0006 | FDA | FDA-2025-E-0845 | Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY | Notice | Determinations | 2026-04-03 | 2026 | 4 | 2026-04-03 | 2026-06-03 | 2026-04-03 17:34:01 | 2026-06478 | 1 | 0 | 09000064b924dac3 |
| FDA-2025-E-0866-0006 | FDA | FDA-2025-E-0866 | Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY | Notice | Determinations | 2026-04-03 | 2026 | 4 | 2026-04-03 | 2026-06-03 | 2026-04-03 17:42:13 | 2026-06478 | 1 | 0 | 09000064b924ccce |
| FDA-2025-E-0372-0005 | FDA | FDA-2025-E-0372 | Determination of Regulatory Review Period for Purposes of Patent Extension; ZIIHERA | Notice | Determinations | 2026-04-03 | 2026 | 4 | 2026-04-03 | 2026-06-03 | 2026-04-03 17:52:42 | 2026-06476 | 1 | 0 | 09000064b924da88 |
| FDA-2025-E-3074-0006 | FDA | FDA-2025-E-3074 | Determination of Regulatory Review Period for Purposes of Patent Extension; EMRELIS | Notice | Determinations | 2026-04-03 | 2026 | 4 | 2026-04-03 | 2026-06-03 | 2026-04-03 17:57:30 | 2026-06480 | 1 | 0 | 09000064b924c470 |
| FDA-2025-E-0871-0006 | FDA | FDA-2025-E-0871 | Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY | Notice | Determinations | 2026-04-03 | 2026 | 4 | 2026-04-03 | 2026-06-03 | 2026-04-03 17:49:10 | 2026-06478 | 1 | 0 | 09000064b924c46e |
| FDA-2025-E-3073-0006 | FDA | FDA-2025-E-3073 | Determination of Regulatory Review Period for Purposes of Patent Extension; EMRELIS | Notice | Determinations | 2026-04-03 | 2026 | 4 | 2026-04-03 | 2026-06-03 | 2026-04-03 17:55:54 | 2026-06480 | 1 | 0 | 09000064b924da86 |
| FDA-2025-E-3626-0006 | FDA | FDA-2025-E-3626 | Determination of Regulatory Review Period for Purposes of Patent Extension; ENFLONSIA | Notice | Determinations | 2026-04-03 | 2026 | 4 | 2026-04-03 | 2026-06-03 | 2026-04-03 17:59:57 | 2026-06479 | 1 | 0 | 09000064b924d98d |
| FDA-2025-E-0870-0006 | FDA | FDA-2025-E-0870 | Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY | Notice | Determinations | 2026-04-03 | 2026 | 4 | 2026-04-03 | 2026-06-03 | 2026-04-03 17:48:07 | 2026-06478 | 1 | 0 | 09000064b924c46d |
| FDA-2026-N-2740-0001 | FDA | FDA-2026-N-2740 | Agency Information Collection Activities; Proposed Collection; Comment Request; Customer/Partner Customer Service Satisfaction Surveys | Notice | 60 Day Proposed Information Collection | 2026-04-03 | 2026 | 4 | 2026-04-03 | 2026-06-03 | 2026-04-03 17:29:44 | 2026-06482 | 1 | 0 | 09000064b924dac4 |
| FDA-2025-E-0868-0006 | FDA | FDA-2025-E-0868 | Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY | Notice | Determinations | 2026-04-03 | 2026 | 4 | 2026-04-03 | 2026-06-03 | 2026-04-03 17:44:23 | 2026-06478 | 1 | 0 | 09000064b924c0e1 |
| FDA-2025-E-0865-0006 | FDA | FDA-2025-E-0865 | Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY | Notice | Determinations | 2026-04-03 | 2026 | 4 | 2026-04-03 | 2026-06-03 | 2026-04-03 17:39:45 | 2026-06478 | 1 | 0 | 09000064b924cccd |
| FDA-2025-E-1672-0007 | FDA | FDA-2025-E-1672 | Determination of Regulatory Review Period for Purposes of Patent Extension; ENCELTO | Notice | Determinations | 2026-04-03 | 2026 | 4 | 2026-04-03 | 2026-06-03 | 2026-04-03 18:06:28 | 2026-06477 | 1 | 0 | 09000064b924d940 |
| FDA-2014-E-2328-0006 | FDA | FDA-2014-E-2328 | Determination of Regulatory Review Period for Purposes of Patent Extension; INJECTAFER | Notice | Determinations | 2026-04-03 | 2026 | 4 | 2026-04-03 | 2026-06-03 | 2026-04-03 18:09:13 | 2026-06483 | 1 | 0 | 09000064b924d4f5 |
| FDA-2025-E-0864-0006 | FDA | FDA-2025-E-0864 | Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY | Notice | Determinations | 2026-04-03 | 2026 | 4 | 2026-04-03 | 2026-06-03 | 2026-04-03 17:38:27 | 2026-06478 | 1 | 0 | 09000064b924cccc |
| FDA-2025-E-0872-0006 | FDA | FDA-2025-E-0872 | Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY | Notice | Determinations | 2026-04-03 | 2026 | 4 | 2026-04-03 | 2026-06-03 | 2026-04-03 17:50:02 | 2026-06478 | 1 | 0 | 09000064b924c46f |
| FDA-2025-E-0158-0006 | FDA | FDA-2025-E-0158 | Determination of Regulatory Review Period for Purposes of Patent Extension; HYMPAVZI | Notice | Determinations | 2026-04-03 | 2026 | 4 | 2026-04-03 | 2026-06-03 | 2026-04-03 18:04:00 | 2026-06481 | 1 | 0 | 09000064b924d942 |
| FDA-2025-E-0867-0006 | FDA | FDA-2025-E-0867 | Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY | Notice | Determinations | 2026-04-03 | 2026 | 4 | 2026-04-03 | 2026-06-03 | 2026-04-03 17:43:31 | 2026-06478 | 1 | 0 | 09000064b924c0e0 |
| FDA-2025-E-0869-0006 | FDA | FDA-2025-E-0869 | Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY | Notice | Determinations | 2026-04-03 | 2026 | 4 | 2026-04-03 | 2026-06-03 | 2026-04-03 17:45:32 | 2026-06478 | 1 | 0 | 09000064b924ba07 |
| FDA-2026-N-0499-0002 | FDA | FDA-2026-N-0499 | Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Hazard Analysis and Critical Control Point Procedures for the Safe and Sanitary Processing and Importing of Juice | Notice | 30 Day Proposed Information Collection | 2026-04-30 | 2026 | 4 | 2026-04-30 | 2026-06-02 | 2026-04-30 17:46:42 | 2026-08417 | 1 | 0 | 09000064b92b80f2 |
| FDA-2026-N-0809-0001 | FDA | FDA-2026-N-0809 | Recommendations on Scale-Up and Postapproval Changes Guidances for Industry; Request for Comments | Notice | Request for Comments | 2026-03-03 | 2026 | 3 | 2026-03-03 | 2026-06-02 | 2026-05-07 09:00:19 | 2026-04196 | 1 | 0 | 09000064b91ed501 |
| FDA-2026-N-2476-0001 | FDA | FDA-2026-N-2476 | Advancing the Use of Digital Health Technologies in Clinical Investigations for Drugs and Biological Products; Request for Information and Comments | Notice | Request for Comments | 2026-03-31 | 2026 | 3 | 2026-03-31 | 2026-06-02 | 2026-05-17 09:00:21 | 2026-06184 | 1 | 0 | 09000064b92439d6 |
| FDA-2026-N-4390-0001 | FDA | FDA-2026-N-4390 | AI-Enabled Optimization of Early- Phase Clinical Trials Pilot Program; Request for Information | Notice | Requests for Information (RFI) | 2026-04-29 | 2026 | 4 | 2026-04-29 | 2026-05-30 | 2026-05-17 09:00:24 | 2026-08281 | 1 | 0 | 09000064b92b54c8 |
| FDA-2026-N-3962-0001 | FDA | FDA-2026-N-3962 | Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments— United States (U.S.) 2026–2027 Formula for COVID–19 Vaccine Composition | Notice | Request for Comments | 2026-04-27 | 2026 | 4 | 2026-04-27 | 2026-05-28 | 2026-05-17 09:00:24 | 2026-08122 | 1 | 0 | 09000064b92ad21d |
| FDA-2026-N-2642-0001 | FDA | FDA-2026-N-2642 | Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke; Established List Additions and Request for Comments | Notice | Request for Comments | 2026-04-23 | 2026 | 4 | 2026-04-23 | 2026-05-27 | 2026-05-16 09:00:16 | 2026-07910 | 1 | 0 | 09000064b92a4e3b |
| FDA-2024-E-5140-0006 | FDA | FDA-2024-E-5140 | Determination of Regulatory Review Period for Purposes of Patent Extension; ENVISION MAMMOGRAPHY PLATFORM | Notice | Determinations | 2025-11-24 | 2025 | 11 | 2025-11-24 | 2026-05-27 | 2026-01-24 13:16:48 | 2025-20667 | 1 | 0 | 09000064b908e3f0 |
| FDA-2024-E-5139-0006 | FDA | FDA-2024-E-5139 | Determination of Regulatory Review Period for Purposes of Patent Extension; ENVISION MAMMOGRAPHY PLATFORM | Notice | Determinations | 2025-11-24 | 2025 | 11 | 2025-11-24 | 2026-05-27 | 2026-01-24 13:16:48 | 2025-20667 | 1 | 0 | 09000064b908e3ef |
| FDA-2024-E-5141-0006 | FDA | FDA-2024-E-5141 | Determination of Regulatory Review Period for Purposes of Patent Extension; ENVISION MAMMOGRAPHY PLATFORM | Notice | Determinations | 2025-11-24 | 2025 | 11 | 2025-11-24 | 2026-05-27 | 2026-01-24 13:16:50 | 2025-20667 | 1 | 0 | 09000064b9092f99 |
| FDA-2024-E-5681-0006 | FDA | FDA-2024-E-5681 | Determination of Regulatory Review Period for Purposes of Patent Extension; ALTIUS DIRECT ELECTRICAL NERVE STIMULATION SYSTEM | Notice | Determinations | 2025-11-24 | 2025 | 11 | 2025-11-24 | 2026-05-27 | 2025-11-24 19:32:14 | 2025-20668 | 1 | 0 | 09000064b9093521 |
| FDA-2026-N-2365-0001 | FDA | FDA-2026-N-2365 | Agency Information Collection Activities; Proposed Collection; Comment Request; Reporting Associated With Animal Drug and Animal Generic Drug User Fees | Notice | 60 Day Proposed Information Collection | 2026-03-23 | 2026 | 3 | 2026-03-23 | 2026-05-23 | 2026-03-23 17:37:47 | 2026-05620 | 1 | 0 | 09000064b922c25e |
| FDA-2026-N-2364-0001 | FDA | FDA-2026-N-2364 | Agency Information Collection Activities; Proposed Collection; Comment Request; Food and Drug Administration Advisory Committees | Notice | 60 Day Proposed Information Collection | 2026-03-23 | 2026 | 3 | 2026-03-23 | 2026-05-23 | 2026-03-25 09:00:29 | 2026-05623 | 1 | 0 | 09000064b922c187 |
| FDA-2026-N-1849-0001 | FDA | FDA-2026-N-1849 | Agency Information Collection Activities; Proposed Collection; Comment Request; Premarket Notifications Submission | Notice | 60 Day Proposed Information Collection | 2026-03-19 | 2026 | 3 | 2026-03-19 | 2026-05-19 | 2026-03-19 17:24:48 | 2026-05329 | 1 | 0 | 09000064b9224334 |
| FDA-2026-N-2279-0001 | FDA | FDA-2026-N-2279 | Preparation for International Cooperation on Cosmetics Regulation Twentieth Annual Meeting (ICCR–20); Request for Comments | Notice | Request for Comments | 2026-03-18 | 2026 | 3 | 2026-03-18 | 2026-05-19 | 2026-05-12 09:00:12 | 2026-05280 | 1 | 0 | 09000064b922165c |
Advanced export
JSON shape: default, array, newline-delimited, object
CREATE TABLE documents (
id TEXT PRIMARY KEY,
agency_id TEXT,
docket_id TEXT,
title TEXT,
document_type TEXT,
subtype TEXT,
posted_date TEXT,
posted_year INTEGER,
posted_month INTEGER,
comment_start_date TEXT,
comment_end_date TEXT,
last_modified TEXT,
fr_doc_num TEXT,
open_for_comment INTEGER,
withdrawn INTEGER,
object_id TEXT
);
CREATE INDEX idx_docs_agency ON documents(agency_id);
CREATE INDEX idx_docs_comment_end ON documents(comment_end_date);
CREATE INDEX idx_docs_withdrawn ON documents(withdrawn);
document_type 1